Study #2024-1179
Phase 1/1b First-In-Human Study Of Autologous Chimeric Engulfment Receptor T-Cell CER-1236 In Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, And Myelofibrosis (Certaint-1)
MD Anderson Study Status
Enrolling
Treatment Agent
CER-1236, Cyclophosphamide, Fludarabine, Mesna
Description
This is a first in human, multi center, open label, phase 1/1b study to evaluate the safety and preliminary efficacy of CER-1236 in patients with relapsed/refractory (R/R), measurable residual disease (MRD) positive acute myeloid leukemia (AML), or TP53mut disease.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
AML, Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Study phase:
Phase I
Physician name:
Abhishek Maiti
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop UT MD Anderson
Show your support for our mission through branded merchandise.